Subscription Center
May 22, 2009 | 5
Drug companies need little arm-twisting when it comes to investing their resources into diseases that afflict millions. But what about a disease that affects only a few thousand people?
To stimulate drug development for diseases with few paying customers – whether due to its sheer rarity or its sufferers’ poverty – the National Institutes of Health (NIH) has committed $120 million over five years to a new program called Therapeutics for Rare and Neglected Disease (TRND). The new trans-NIH program aims to support researchers with more money for in-house NIH studies and additional funds for external academic, advocacy and foundation collaborations.
See what we're tweeting about
Horganism Call me a fool, but I still have hope Obama will start leading us to a world without war. http://t.co/SrQprqdj4m Horganism New essay on Thomas Nagel's anti-materialist "Mind and Cosmos," plus mine: http://t.co/AgG1ikLMhC http://t.co/W1qDxNezZC
notscientific #SciLogs Weekly Roundup: Charles Darwin, Biocalculator, Infotainment, Woman Scientist, National Champion For Science http://t.co/gnfWhgKaHF
Deadline: Aug 31 2013
Reward: $100,000 USD
The Geoffrey Beene Foundation Alzheimer’s Initiative (GBFAI) is launching the 2013 Geoffrey Beene Global NeuroDiscovery Challenge whose
Deadline: Jul 30 2013
Reward: $100,000 USD
The Seeker desires a method for producing pseudoephedrine products in such a way that it will be extremely difficult for clandestine che
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
